A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 184
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : PPA
Long Form : phenylpropanolamine
No. Year Title Co-occurring Abbreviation
1978 Three anorectic drugs: similar structures but different effects on brain and behavior. ---
1982 Oral vasoconstrictors in perennial non-allergic rhinitis. DHE
1982 The glycemic effects of sympathomimetics in stressed mice. EPD, PSD
1983 Comparison of effects of two dosage regimens of phenylpropanolamine on blood pressure and plasma levels in normal subjects under steady-state conditions. ---
1983 Glycemic response to selected sympathomimetics in stressed normal and goldthioglucose mice. GTG, PE, PSD
1983 Stress incontinence in females: treatment with phenylpropanolamine. A urodynamic and pharmacological evaluation. MUCP
1984 Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine. same dose
1984 Dose-response relationship of a topical nasal decongestant: phenylpropanolamine. ---
1984 Urethral sphincteric insufficiency in postmenopausal females: treatment with phenylpropanolamine and estriol separately and in combination. A urodynamic and clinical evaluation. ---
10  1985 Caffeine-phenylethylamine combinations mimic the amphetamine discriminative cue. ---
11  1985 Comparison of brown adipose tissue thermogenesis induced by congeners and isomers of phenylpropanolamine. AMP, EPH, MET, NOR, PS
12  1985 Effects of exposure to stressful stimuli on the free-choice consumption of various phenethylamines by rats. AMP, MET
13  1985 Intracranial hemorrhages due to phenylpropanolamine. ---
14  1985 Propranolol antagonism of phenylpropanolamine-induced hypertension. ---
15  1985 The effect of topical phenylpropanolamine on nasal secretion and nasal airway resistance after histamine challenge in man. NAR
16  1985 Therapeutic doses of phenylpropanolamine increase supine systolic blood pressure. BP
17  1986 Effects of phenylpropanolamine on gastric retention in the adult rat. ---
18  1986 Effects of phenylpropanolamine on ostial and nasal airway resistance in healthy individuals. OAR
19  1986 Inhibition of monoamine oxidase activity by phenylpropanolamine, an anorectic agent. MAO
20  1986 The discriminative stimulus and subjective effects of phenylpropanolamine, mazindol and d-amphetamine in humans. AMP, DS, MAZ
21  1986 The effect of phenylpropanolamine on ambulatory blood pressure. ---
22  1986 Weight loss induced by chronic phenylpropanolamine: anorexia and brown adipose tissue thermogenesis. BW, FI, IBAT, WI
23  1987 Assessment of the effects of phenylpropanolamine on appetite and food intake. ---
24  1987 Blinding, unblinding, and the placebo effect: an analysis of patients' guesses of treatment assignment in a double-blind clinical trial. ---
25  1987 Cerebral infarction with a single oral dose of phenylpropanolamine. ---
26  1987 Intracranial hemorrhage and cerebral angiopathic changes in a suicidal phenylpropanolamine poisoning. ---
27  1987 Myocardial necrosis due to intraperitoneal administration of phenylpropanolamine in rats. ---
28  1987 Phenylpropanolamine in treatment of female stress urinary incontinence. Double-blind placebo controlled study in 24 patients. MUCP
29  1987 Phenylpropanolamine pharmacokinetics in dogs after intravenous, oral, and oral controlled-release doses. HPLC
30  1987 Phenylpropanolamine: an over-the-counter drug causing central nervous system vasculitis and intracerebral hemorrhage. Case report and review. CNS
31  1987 Phenylpropanolamine: effects on subjective and cardiovascular variables at recommended over-the-counter dose levels. mood, SR
32  1987 The effects of phenylpropanolamine on food intake and body weight in the genetically obese (ob/ob) mouse. ---
33  1988 Effect of phenylpropanolamine on diet selection in rats. ---
34  1988 Effects of phenylpropanolamine and isometric exercise on blood pressure. ---
35  1988 Estrogens and phenylpropanolamine in combination for stress urinary incontinence in postmenopausal women. ---
36  1988 Inhibition of feeding and hoarding behaviors by phenylpropanolamine in the adult rat. ---
37  1988 pH-dependent swelling and solute diffusion characteristics of poly(hydroxyethyl methacrylate-co-methacrylic acid) hydrogels. TEGDMA
38  1988 Psychiatric side effects attributed to phenylpropanolamine. ---
39  1988 The effects of phenylpropanolamine on human sympathetic nervous system function. BP, CA, SNS
40  1988 [Benign cerebral angiopathies and phenylpropanolamine]. ---
41  1989 A double-blind clinical evaluation of the anorectic activity of phenylpropanolamine versus placebo. ---
42  1989 Determinants of the pressor effect of phenylpropanolamine in healthy subjects. ---
43  1989 Hollow fibers as an oral sustained-release delivery system. ---
44  1989 Phenylpropanolamine and amphetamine disrupt postprandial satiety in rats. AM
45  1989 Phenylpropanolamine potentiates caffeine neurotoxicity in rats. CSF
46  1989 Self-administration of phenylpropanolamine (PPA) by rats previously trained to self-administer amphetamine. ---
47  1989 Subjective profile of phenylpropanolamine: absence of stimulant or euphorigenic effects at recommended dose levels. ---
48  1989 The effect of phenylpropanolamine on blood pressure during upright bicycle exercise in normal subjects. ---
49  1989 Transient hypertension after two phenylpropanolamine diet aids and the effects of caffeine: a placebo-controlled follow-up study. BP
50  1990 A dose-ranging study of phenylpropanolamine on nasal airflow. ---
51  1990 A review of the physiological bases of the anorexic action of phenylpropanolamine (d,1-norephedrine). ---
52  1990 Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. ADRs, OTC
53  1990 Conditioned taste reactivity in rats after phenylpropanolamine, d-amphetamine or lithium chloride. LiCl, TRT
54  1990 Diurnal variation of phenylpropanolamine anorexia in rats. ---
55  1990 Effect of combined treatment with phenylpropanolamine and estriol, compared with estriol treatment alone, in postmenopausal women with stress urinary incontinence. ---
56  1990 Effects of haloperidol on anorexia induced by l-norephedrine and d-amphetamine in adult rats. ---
57  1990 Effects of paraventricular hypothalamic microinjections of phenylpropanolamine and d-amphetamine on mash intake in rats. PVN
58  1990 Effects of perifornical hypothalamic microinjections of phenylpropanolamine and amphetamine on latency to feed and mash intake in rats. PFH
59  1990 Evaluation of the pharmacological similarities between phenylpropanolamine and amphetamine: effects on schedule-controlled behavior. DOPAC, FR-5
60  1990 Phenylpropanolamine and caffeine use among diet center clients. ADRs, OTC
61  1990 Serum concentrations of phenylpropanolamine and associated effects on blood pressure in normotensive subjects: a pilot-study. BP
62  1990 Steady state pharmacokinetics and dose-proportionality of phenylpropanolamine in healthy subjects. ---
63  1990 The pharmacology of the anorexic effect of phenylpropanolamine. PFH
64  1991 Effects of circadian cycle and time of testing on drug-induced anorexia in rats. ---
65  1991 Effects of sympathomimetic agents on opiate analgesia, tolerance and dependence in mice. ---
66  1991 Enhancement of phenylpropanolamine anorexia by proglumide in rats. CCK
67  1991 In-vivo pharmacokinetic characteristics of a transdermal phenylpropanolamine (PPA) preparation. PPA.HCl
68  1991 L-tyrosine fails to potentiate several peripheral actions of the sympathomimetics. AMP, EPH, L-Tyr
69  1991 Reversal of phenylpropanolamine anorexia in rats by the alpha-1 receptor antagonist benoxathian. PVN
70  1991 Role of adrenoceptors in the potentiation of opioid antinociception by ephedrine and phenylpropanolamine in mice. i.p, s.c
71  1991 Stereospecific high-performance liquid chromatographic assay for the enantiomers of phenylpropanolamine in human plasma. ---
72  1991 Suppression of feeding induced by phenylephrine microinjections within the paraventricular hypothalamus in rats. NE, PVN
73  1991 The effect of multiple doses of phenylpropanolamine on the blood pressure of patients whose hypertension was controlled with beta blockers. ---
74  1992 Clinical studies with phenylpropanolamine: a metaanalysis. ---
75  1992 Comparative brain levels of phenylpropanolamine and amphetamine in rats. ---
76  1992 Cytotoxic and morphological effects of phenylpropanolamine, caffeine, nicotine, and some of their metabolites studied In vitro. ENDO
77  1992 Drug discrimination studies in rats with caffeine and phenylpropanolamine administered separately and as mixtures. ---
78  1992 Effectiveness of phenylpropanolamine in the management of moderate obesity. DB
79  1992 Effects of adrenalectomy and deprivation condition on food intake after phenylpropanolamine or clonidine. CLON, PVN, SHAM
80  1992 Effects of L-tyrosine on mixed-acting sympathomimetic-induced pressor actions. EPH, L-Tyr
81  1992 Evaluation of six commercial amphetamine and methamphetamine immunoassays for cross-reactivity to phenylpropanolamine and ephedrine in urine. DPC, FPIA, MA
82  1992 Further metabolic studies of codeine and morphine in mice pretreated with sympathomimetics. ---
83  1992 Overview of adrenergic anorectic agents. PFH, PVN
84  1992 Phenylpropanolamine and blood pressure: a review of prospective studies. ---
85  1992 Reversal of cirazoline- and phenylpropanolamine-induced anorexia by the alpha 1-receptor antagonist prazosin. PVN
86  1992 Use of phenylpropanolamine to reduce nicotine cessation induced weight gain in rats. ---
87  1992 [Bioavailability of a controlled-release suspension of phenylpropanolamine in healthy volunteers]. ---
88  1993 An assessment of the involvement of paraventricular hypothalamic alpha 2-adrenoceptors in phenylpropanolamine anorexia. NE, PVN
89  1993 Comparison between phenylpropanolamine and structurally related compounds on gastric transit in the rat. ---
90  1993 Effect of phenylpropanolamine and related compounds on beta-adrenoceptor-induced activation of adenylyl cyclase. cAMP, EPI, NE
91  1993 Effect of phenylpropanolamine on energy expenditure and weight loss in overweight women. BMR, EE, OROS, RQ
92  1993 Effects of intra-PVN injections of d- and l-norephedrine on feeding in rats. NEP, PVN
93  1993 Effects of phenylpropanolamine infusion and withdrawal on body weight and dietary composition in male and female rats. ---
94  1993 Effects on food and water intake of the alpha 1-adrenoceptor agonists amidephrine and SK&F-89748. PVN
95  1993 Lack of involvement of 4-hydroxynorephedrine in phenylpropanolamine-induced anorexia in rats. ---
96  1993 National Association of Medical Examiners Pediatric Toxicology Registry. Report 2: Phenylpropanolamine update. NAME, PedTox
97  1993 The discriminative stimulus properties of legal, over-the-counter stimulants administered singly and in binary and ternary combinations. AMPHET, CAF, COC, EPHED, OTC, SAL
98  1994 Conditioned taste aversion in rats induced by the alpha 1-adrenoceptor agonist cirazoline. CTA, PVN
99  1994 Phenylpropanolamine-induced psychosis. Potential predisposing factors. ---
100  1995 An experimental model for long-term examinations of urethral and uterine pressures in conscious dogs: effect of a highly selective compound contracting urethral smooth muscles. ---
101  1995 Cerebral arteritis associated with oral use of phenylpropanolamine: report of a case. ---
102  1995 Effects of phenylpropanolamine on withdrawal symptoms. ---
103  1995 Isobolographic assessment of the effects of combinations of phenylpropanolamine and fenfluramine on food intake in rats. FEN, PVN
104  1995 [Comparison of multiple dosage bioavailability between phenylpropanolamine controlled release suspension and conventional tablet in healthy volunteers]. CRS, FI
105  1996 Effects of systemic phenylpropanolamine and fenfluramine on serotonin activity within rat paraventricular hypothalamus. FEN, PFH, PVN
106  1997 Acute administration of phenylpropanolamine fails to affect resting energy expenditure in men of normal weight. REE, RQ
107  1997 Assessment of the role of oxytocin receptors in phenylpropanolamine-induced anorexia in rats. PVN
108  1997 Do pseudoephedrine or phenylpropanolamine improve maximum oxygen uptake and time to exhaustion? BPs, PSE
109  1997 Effects of the alpha 1a-adrenoceptor antagonist RS-17053 on phenylpropanolamine-induced anorexia in rats. ---
110  1997 Hair analysis for drugs of abuse. XIX. Determination of ephedrine and its homologs in rat hair and human hair. EP, MA, ME, PFPA, TFAA
111  1998 Intracerebral hemorrhage in a young woman with arteriovenous malformation after taking diet control pills containing phenylpropanolamine: a case report. ---
112  1999 Changes in nasal resistance and nasal geometry using pressure and acoustic rhinometry in a feline model of nasal congestion. AcR, NAR
113  1999 Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. AcR, CLOB, NAR, RAN, THIO
114  1999 Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity. ---
115  1999 Effects of sustained-release oral phenylpropanolamine on the nasal mucosa of healthy subjects. ---
116  1999 Validation of cough-induced leak point pressure measurement in the evaluation of pharmacological treatment of stress incontinence. CILPP, MUP
117  2000 Inhibition of nitric oxide synthase enhances the myocardial toxicity of phenylpropanolamine. L-NAME
118  2001 HPLC determination of phenylpropanolamine in pharmaceutical preparations using 4-dimethylaminobenzaldehyde as a derivatizing reagent. DAB, HPLC
119  2001 Influence of a combination of herbs on appetite suppression and weight loss in rats. ---
120  2001 MCC resolves on phenylpropanolamine (PPA) safety. ---
121  2001 Pharmacological properties of A-204176, a novel and selective alpha1A adrenergic agonist, in in vitro and in vivo models of urethral function. ---
122  2001 Phenylpropanolamine and stroke: the study, the FDA ruling, the implications. ---
123  2001 Tyrosine improves behavioral and neurochemical deficits caused by cold exposure. AMPH, NE, SAL, Tyr
124  2002 Effects of selegiline, phenylpropanolamine, or a combination of both on physiologic and behavioral variables in healthy dogs. ---
125  2002 HPLC determination of phenylpropanolamine in pharmaceutical OTC preparations. CPA, OTC, PE
126  2002 Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. PANSS
127  2002 Regulatory decisions in a globalised world: the domino effect of phenylpropanolamine withdrawal in Latin America. FDA
128  2003 Both alpha1-adrenergic and D(1)-dopaminergic neurotransmissions are involved in phenylpropanolamine-mediated feeding suppression in mice. DA
129  2003 Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction. ---
130  2003 Ephedrines in over-the-counter cold medicines and urine specimens collected during sport competitions. EPH, GC-NPD, IOC, MEPH, MS, OTC, PEPH
131  2003 Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). BP, EFS, GP, HSV
132  2003 Phenylpropanolamine and intracranial hemorrhage risk in a Mexican population. ICH, SAH
133  2003 Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. ---
134  2003 The effect of GnRH analogs on urinary incontinence after ablation of the ovaries in dogs. ---
135  2004 Antioxidant-independent ascorbate enhancement of catecholamine-induced contractions of vascular smooth muscle. EPH, NE
136  2004 Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication. FDA
137  2004 Evaluation of ephedrine, pseudoephedrine and phenylpropanolamine concentrations in human urine samples and a comparison of the specificity of DRI amphetamines and Abuscreen online (KIMS) amphetamines screening immunoassays. AMP, EPH, GC/MS, MDA, MDMA, MTH, PSEPH
138  2004 High performance liquid chromatography with fluorescence detection for the determination of phenylpropanolamine in human plasma and rat's blood and brain microdialysates using DIB-Cl as a label. DIB-Cl, EP, FL
139  2004 Immunohistochemical and genomic evidence for the involvement of hypothalamic neuropeptide Y (NPY) in phenylpropranolamine-mediated appetite suppression. NPY
140  2004 Pharmacokinetic interactions between phenylpropanolamine, caffeine and chlorpheniramine in rats. ---
141  2004 Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist. IUP, MAP
142  2005 A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women. ---
143  2005 Reparation of controlled release spheronized beads by simple extrusion and modified spheronization process. ---
144  2005 Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. DP, LC-MS, LOR, PES
145  2006 Capillary gas chromatographic determination of phenylpropanolamine in pharmaceutical preparation. RSD
146  2006 Metabolites of ephedrines in human urine after administration of a single therapeutic dose. EPH, GC-MS, MEPH, OTC, PEPH, TBME, TFAA
147  2006 Phenylpropanolamine and hemorrhagic stroke in the Hemorrhagic Stroke Project: a reappraisal in the context of science, the Food and Drug Administration, and the law. FDA, HSP
148  2007 Effect of phenylpropanolamine and pseudoephedrine on the urethral pressure profile and continence scores of incontinent female dogs. PD
149  2007 Phenylpropanolamine contained in cold remedies and risk of hemorrhagic stroke. HS
150  2007 Protracted 'pro-addictive' phenotype produced in mice by pre-adolescent phenylpropanolamine. OTC
151  2007 Roles of central catecholamine and hypothalamic neuropeptide Y genome in the development of tolerance to phenylpropanolamine-mediated appetite suppression. CAT, NPY
152  2007 Transcript of protein kinase A knock-down modulates feeding behavior and neuropeptide Y gene expression in phenylpropanolamine-treated rats. CREB, NPY, PKA, POMC
153  2007 [Efficacy, tolerance and acceptability of Incontex in spayed bitches with urinary incontinence]. ---
154  2008 Are non-prescription medications needed for weight control? FDA, OTC
155  2008 Interrupting activator protein-1 signaling in conscious rats can modify neuropeptide Y gene expression and feeding behavior of phenylpropanolamine. AP-1, NPY, SOD
156  2008 Protracted 'anti-addictive' effects of adolescent phenylpropanolamine exposure in C57BL/6J mice. NAc, OTC
157  2008 Transcriptional interruption of cAMP response element binding protein modulates superoxide dismutase and neuropeptide Y-mediated feeding behavior in freely moving rats. CREB, NPY, SOD-2
158  2009 Boltushka: a homemade amphetamine-type stimulant and HIV risk in Odessa, Ukraine. ATSs, IDUs, RPAR
159  2009 Influences of urinary pH on the pharmacokinetics of three amphetamine-type stimulants using a new high-performance liquid chromatographic method. ASC, ATS, AUC, FEN, HPLC, MRT, PSE
160  2009 Interventions for preventing weight gain after smoking cessation. CBT, RR
161  2009 Roles of protein kinase Calpha isozyme in the regulation of oxidative stress and neuropeptide Y gene expression in phenylpropanolamine-mediated appetite suppression. NPY, PKC, POMC, SOD
162  2010 A New Spectrophotometric Method for Determination of Phenylpropanolamine HCl in its Pharmaceutical Formulations via Reaction with 2,3,5,6-tetrachloro-1,4-benzoquinone. LOD, LOQ
163  2010 Combined pharmacokinetic and urodynamic study of the effects of oral administration of phenylpropanolamine in female Beagle dogs. USMI
164  2010 The effect of protein kinase C-delta knockdown on anti-free radical enzyme and neuropeptide Y gene expression in phenylpropanolamine-treated rats. CAT, NOS, NPY, PKC
165  2011 Artificial neural network combined with principal component analysis for resolution of complex pharmaceutical formulations. ANN, CAF, MEP, PCA, PCs, PLS2, PNA, SEP
166  2011 Clinical evaluation of a single daily dose of phenylpropanolamine in the treatment of urethral sphincter mechanism incompetence in the bitch. BW, UPP, USMI
167  2011 Effects of phenylpropanolamine (PPA) on in vitro human erythrocyte membranes and molecular models. DMPC, DMPE, IUM, LUV, SEM
168  2011 Posterior reversible encephalopathy syndrome complicating intracranial hemorrhage after phenylpropanolamine exposure. ICH, PRES
169  2011 Role of reactive oxygen species-related enzymes in neuropeptide y and proopiomelanocortin-mediated appetite control: a study using atypical protein kinase C knockdown. aPKC, NPY, POMC, ROS-RE
170  2011 Spectrophotometric determination of certain CNS stimulants in dosage forms and spiked human urine via derivatization with 2,4-Dinitrofluorobenzene. DNFB, EPH, LOD, LOQ, PSE
171  2012 Determination of the active principles of Catha Edulis: quali-quantitative analysis of cathinone, cathine, and phenylpropanolamine. ---
172  2012 Knocking down the transcript of NF-kappaB modulates the reciprocal regulation of endogenous antioxidants and feeding behavior in phenylpropanolamine-treated rats. GPx, NPY, SOD
173  2012 Urodynamic and haemodynamic effects of a single oral administration of ephedrine or phenylpropanolamine in continent female dogs. UPP
174  2013 Inhibiting neuropeptide Y Y1 receptor modulates melanocortin receptor- and NF-kappaB-mediated feeding behavior in phenylpropanolamine-treated rats. MC4R, NF-kappaB, NPY, Y1R
175  2013 Neuropeptide Y Y1 receptor knockdown can modify glutathione peroxidase and c-AMP response element-binding protein in phenylpropanolamine-treated rats. CREB, GP, NPY, Y1R
176  2013 Systemic hypertension and hypertensive retinopathy following PPA overdose in a dog. AST, CK, OU
177  2013 The identification of neuropeptide Y receptor subtype involved in phenylpropanolamine-induced increase in oxidative stress and appetite suppression. NPY, SOD, Y1R, Y5R
178  2014 Gonadotropin-releasing hormone immunization for the treatment of urethral sphincter mechanism incompetence in ovariectomized bitches. ---
179  2015 Changes in blood pressure following escalating doses of phenylpropanolamine and a suggested protocol for monitoring. BW
180  2015 Targeting oxidative stress in the hypothalamus: the effect of transcription factor STAT3 knockdown on endogenous antioxidants-mediated appetite control. JAK2, NPY, POMC, ROS, STAT3
181  2016 Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. FDA, SR
182  2017 Mediation of oxidative stress in hypothalamic ghrelin-associated appetite control in rats treated with phenylpropanolamine. AG, CART, GOAT, NPY
183  2017 Simultaneous determination of cetirizine, phenyl propanolamine and nimesulide using third derivative spectrophotometry and high performance liquid chromatography in pharmaceutical preparations. CET, CTZ, NMS
184  2018 Myocardial hypertrophy associated with long-term phenylpropanolamine use in a dog. ---